Literature DB >> 18289694

Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action.

Masaharu Shinkai1, Markus O Henke, Bruce K Rubin.   

Abstract

Macrolide antibiotics administered in sub-antimicrobial doses improve pulmonary function and decrease exacerbation frequency for persons with diffuse panbronchiolitis or cystic fibrosis. Data also suggest a beneficial effect of macrolide antibiotics in the treatment of steroid dependent asthma. Many potential immunomodulatory effects of macrolide antibiotics have been reported including the ability to down-regulate prolonged inflammation, decreasing airway mucus secretion, inhibiting bacterial biofilm, decreasing the production of reactive oxygen species, inhibiting neutrophil activation and mobilization, accelerating neutrophil apoptosis, and blocking the activation of nuclear transcription factors. Macrolides initially decrease, then increase, and have finally a sustained suppression of cytokine secretions from normal human bronchial epithelial cells through inhibition and activation of extracellular signal-regulated kinases (ERK) and then reversibly retard cell proliferation probably through ERK. Consistent with this, macrolide antibiotics possibly reduce mucin production as well as neutrophil migration by interfering with ERK signal transduction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18289694     DOI: 10.1016/j.pharmthera.2007.11.001

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  64 in total

1.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 2.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

Review 3.  Chronic Rhinosinusitis without Nasal Polyps.

Authors:  Seong Ho Cho; Dae Woo Kim; Philippe Gevaert
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Jul-Aug

Review 4.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

5.  Azithromycin distinctively modulates classical activation of human monocytes in vitro.

Authors:  M Vrančić; M Banjanac; K Nujić; M Bosnar; T Murati; V Munić; D Stupin Polančec; D Belamarić; M J Parnham; V Eraković Haber
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 6.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

7.  Wheezing and asthma may be enhanced by broad spectrum antibiotics used in early childhood. Concept and results of a pharmacoepidemiology study.

Authors:  W Jedrychowski; F Perera; U Maugeri; E Mroz; E Flak; M Perzanowski; R Majewska
Journal:  J Physiol Pharmacol       Date:  2011-04       Impact factor: 3.011

Review 8.  Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma.

Authors:  Pieter Bogaert; Kurt G Tournoy; Thomas Naessens; Johan Grooten
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

9.  Chronic cough and obstructive sleep apnea in a community-based pulmonary practice.

Authors:  Krishna M Sundar; Sarah E Daly; Michael J Pearce; William T Alward
Journal:  Cough       Date:  2010-04-15

10.  Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Authors:  Carla Maria P Ribeiro; Harry Hurd; Yichao Wu; Mary E B Martino; Lisa Jones; Brian Brighton; Richard C Boucher; Wanda K O'Neal
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.